0.91 USD
↗ 0.06 (6.52%)AT CLOSE (11:59 AM EDT)
Senti Biosciences, Inc. Common Stock
SNTINASDAQ • USD
0.93
↗ 0.00 (0.32%)
POST MARKET (AS OF 04:48 PM EDT)
Post Market
AS OF 04:48 PM EDT
0.93
↗ 0.00 (0.32%)
Market: OPEN
Open?$0.87
High?$0.93
Low?$0.85
Prev. Close?$0.86
Volume?60.6K
Avg. Volume?126.8K
VWAP?$0.89
Rel. Volume?0.48x
Bid / Ask
Bid?$0.85 × 1.0K
Ask?$0.87 × 1.3K
Spread?$0.02
Midpoint?$0.86
Valuation & Ratios
Market Cap?26.8M
Shares Out?31.1M
Float?10.1M
Float %?38.5%
P/E Ratio?N/A
P/B Ratio?4.79
EPS?-$1.97
Dividend?0.00%
Ex-Dividend?N/A
Technical Outlook
Loading...
Fundamental Outlook
Loading...
Short Interest
Loading...
Financial Health
Current Ratio?1.67Adequate
Quick Ratio?1.67Adequate
Cash Ratio?1.18Strong
Debt/Equity?0.00Low
ValuationFAIRLY VALUED
Score58/100
P/E?N/A▾
P/B?4.79FAIR▾
P/S?1,217.47HIGH▾
P/FCF?N/A▾
EV/EBITDA?-0.2CHEAP▾
EV/Sales?471.10HIGH▾
Returns & Efficiency
ROE?-1,099.3%WEAK▾
ROA?-119.9%WEAK▾
Cash Flow & Enterprise
FCF?$-43640000
Enterprise Value?$10.4M
Related Companies
Loading...
News
Profile
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.
Employees
39
Market Cap
26.7M
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
Listed
2022-06-09
Address
2 CORPORATE DRIVE, FIRST FLOOR
SOUTH SAN FRANCISCO, CA 94080
Phone: (650) 239-2030
SOUTH SAN FRANCISCO, CA 94080
Phone: (650) 239-2030